Vanglusagene ensiparvovec

N/A

Report date: 2025/05/23 14:38:37

Base Information

Drug NameVanglusagene ensiparvovec
Drug Alias NameSPK-GAASPK-3006RG-6359
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVrh74 vector
Mechanisms of ActionGene transferenceAcidic alpha-glucosidase modulators
TargetsAcidic alpha-glucosidase
Therapy Area/IndicationsLysosomal Storage DiseasesHypotensionGlycogen Storage Disease Type II
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSpark Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSpark Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLysosomal Storage DiseasesHypotensionGlycogen Storage Disease Type II
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank